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BACKGROUND & AIMS: In a phase 3 trial (RESORCE),
regorafenib increased overall survival compared with placebo
in patients with hepatocellular carcinoma (HCC) previously
treated with sorafenib. In an exploratory study, we analyzed
plasma and tumor samples from study participants to identify
genetic, microRNA (miRNA), and protein biomarkers associated
with response to regorafenib. METHODS: We obtained
archived tumor tissues and baseline plasma samples from
patients with HCC given regorafenib in the RESORCE trial.
Baseline plasma samples from 499 patients were analyzed for
expression of 294 proteins (DiscoveryMAP) and plasma
samples from 349 patients were analyzed for levels of 750
miRNAs (miRCURY miRNA PCR). Tumor tissues from 7 re-
sponders and 10 patients who did not respond (progressors)
were analyzed by next-generation sequencing (Foundation-
One). Forty-six tumor tissues were analyzed for expression
patterns of 770 genes involved in oncogenic and inflammatory
pathways (PanCancer Immune Profiling). Associations between
plasma levels of proteins and miRNAs and response to treat-
ment (overall survival and time to progression) were evaluated
using a Cox proportional hazards model. RESULTS: Decreased
baseline plasma concentrations of 5 of 266 evaluable proteins
(angiopoietin 1, cystatin B, the latency-associated peptide of
transforming growth factor beta 1, oxidized low-density lipo-
protein receptor 1, and C-C motif chemokine ligand 3; adjusted
P  .05) were significantly associated with increased overall
survival time after regorafenib treatment. Levels of these 5
proteins, which have roles in inflammation and/or HCC path-
ogenesis, were not associated with survival independently of
treatment. Only 20 of 499 patients had high levels and a
reduced survival time. Plasma levels of a-fetoprotein and c-
MET were associated with poor outcome (overall survival)
independently of regorafenib treatment only. We identified 9
plasma miRNAs (MIR30A, MIR122, MIR125B, MIR200A,
MIR374B, MIR15B, MIR107, MIR320, and MIR645) whose
levels significantly associated with overall survival time with
regorafenib (adjusted P  .05). Functional analyses of these
miRNAs indicated that their expression level associated with
increased overall survival of patients with tumors of the
Hoshida S3 subtype. Next-generation sequencing analyses of
tumor tissues revealed 49 variants in 27 oncogenes or tumor
suppressor genes. Mutations in CTNNB1 were detected in 3 of
10 progressors and VEGFA amplification in 1 of 7 responders.
CONCLUSION: We identified expression patterns of plasma
proteins and miRNAs that associated with increased overall
survival times of patients with HCC following treatment with
regorafenib in the RESORCE trial. Levels of these circulatingbiomarkers and genetic features of tumors might be used to
identify patients with HCC most likely to respond to regor-
afenib. ClinicalTrials.gov number NCT01774344. NCBI GEO
accession numbers: mRNA data (NanoString): GSE119220;
miRNA data (Exiqon): GSE119221Keywords: NGS; Predictive; Prognostic Factor; Time to
Progression.
epatocellular carcinoma (HCC) is a heterogeneousHdisease that lacks molecular predictors of response
to available treatments. An analysis of 10 selected bio-
markers for potential response to sorafenib, a multikinase
inhibitor (MKI) approved for the first-line treatment of
unresectable HCC, failed to identify a treatment effect in the
phase 3 SHARP study.1 More recently, the MKI regorafenib
was approved for the treatment of HCC previously treated
with sorafenib, based on the results of the phase 3 RESORCE
trial in which regorafenib improved overall survival (OS)
and time to progression (TTP) vs placebo.2 Predictive
markers of response to regorafenib, including all common
clinical markers, have not been identified in analyses of
other approved regorafenib indications.3,4
As an MKI, regorafenib blocks the activity of multiple
protein kinases involved in angiogenesis, proliferation, the
tumor microenvironment, and metastasis, including
vascular endothelial growth factor receptors (VEGFRs) 1–3,
TIE2, KIT, RET, RAF-1, BRAF, platelet-derived growth
factor receptor, and fibroblast growth factor receptor, as
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Regorafenib is approved for the treatment of
hepatocellular carcinoma (HCC) following sorafenib. The
search for biomarkers associated with response to
regorafenib has so far been unsuccessful.
NEW FINDINGS
The authors identified baseline plasma concentrations of
proteins and miRNAs that were associated with overall
survival time after treatment with regorafenib.
LIMITATIONS
This was an exploratory, retrospective analysis that can
only be considered hypothesis generating.
IMPACT
The authors identified plasma biomarkers that might be
measured to identify patients with HCC most likely to
respond to regorafenib. These findings require validation.
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an HCC preclinical model have confirmed a complex
expression pattern with regorafenib that is different from
that of sorafenib.7 This complex pattern, along with disease
heterogeneity, may make the identification of biomarkers
challenging.
We performed a preplanned, retrospective biomarker
analysis on patients in the RESORCE trial to identify
potentially predictive biomarkers of benefit to regorafenib
in HCC. In the absence of established or predefined bio-
markers for regorafenib, we performed a broad exploratory
biomarker analysis at the DNA, RNA, and protein levels that
represents a much more comprehensive approach than
previous studies of regorafenib or sorafenib.Methods
Study Design and Participants
RESORCE (NCT01774344) was a randomized, double-blind,
placebo-controlled, phase 3 trial. Details of RESORCE have been
published elsewhere.2 Patients with HCC who had radiologic
progression on sorafenib and tolerated sorafenib were ran-
domized 2:1 to oral regorafenib 160 mg once daily or matching
placebo plus best supportive care during weeks 1 to 3 of each
4-week cycle. Treatment continued until disease progression,
clinical progression, death, or unacceptable toxicity. The pri-
mary endpoint was OS (time from randomization to death due
to any cause). TTP (time from randomization to radiologic or
clinical disease progression) was a secondary endpoint.
Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
and modified RECIST (mRECIST) for HCC were used to measure
disease progression. Adverse events were graded using the
National Cancer Institute Common Terminology Criteria for
Adverse Events version 4.03. All patients provided written
informed consent and the trial was approved by the ethics
committee or institutional review board at each center and
complied with Good Clinical Practice guidelines, the Declaration
of Helsinki, and applicable local laws and regulations.Procedures: Archival Tumor Tissue
The collection of archival tumor tissue was optional in
RESORCE, resulting in 68 tissue samples available for the
current study as formalin-fixed paraffin-embedded blocks or as
cut 5-mm sections mounted on glass slides. Of these samples, 23
were selected at random from the regorafenib group for next-
generation sequencing (NGS) and 62 had sufficient RNA for
tumor inflammation gene expression profiling.
Mutational analysis by NGS was carried out using the
FoundationOne gene panel of 315 cancer-related genes
(Foundation Medicine, Inc.) as previously described.8 Samples
for NGS were selected based on their response to regorafenib
treatment (as determined by investigator assessment using
mRECIST) with all available samples from responders included
(12 patients with complete or partial response) and a similar
number of progressors chosen at random (11 patients with
progressive disease).
RNA tumor inflammation gene expression profiling was
conducted using the nCounter PanCancer Immune Profiling
panel v1.1 that included 770 genes covering both the adaptive
and innate immune response (NanoString Technologies, Inc.,
Seattle, WA), as well as 6 customized genes (a 5-gene signature
described as prognostic for HCC [HN1, RAN, RAMP3, KRT19,
TAF9],9 and c-MET), and 14 controls (6 positive, 8 negative).
Tumor inflammation was assessed by immune cell scores
derived from gene expression data using nSolver v3.0 analysis
software (NanoString Technologies, Inc.).
Procedures: Plasma Samples
For plasma-based analysis, K2-EDTA plasma samples were
collected at baseline from all patients enrolled in RESORCE, of
which 499 of 573 samples were of sufficient quality for analysis
of circulating proteins and 349 of 573 had sufficient RNA for
the testing of circulating microRNA (miRNA).
Concentrations of 294 circulating proteins from 499 plasma
samples were quantified using a proprietary multiplex immu-
noassay, DiscoveryMAP v3.3 (Myriad RBM, Austin, TX), using
the Luminex xMAP system. The lower limit of quantification
was defined as the concentration at which the analyte mea-
surements demonstrated a coefficient of variation of 30%.
Protein concentrations were determined from the median of at
least 20 individual measures. Assays were rejected if 50% of
the quality controls for a single analyte were beyond 2 standard
deviations.
Expression levels of 750 circulating miRNAs and 10 con-
trols were quantified by quantitative polymerase chain reaction
(miRCURY LNA microRNA PCR kit; Exiqon, Vedbaek, Denmark)
according to the manufacturer’s protocol. miRNA expression
had to be measurable on a continuous scale or dichotomized by
preprocessing (present vs absent) and be present in 5% of
patients.
Statistical Analysis
The retrospective biomarker analyses reported here were
exploratory and hypothesis generating and were not powered
for statistical significance. Analyses on archival tumor samples
(NGS and immune profiling) were descriptive in nature due to
the small sample size. All analyses were performed with SAS
version 9.2 (SAS Institute, Cary, NC) or later and R software
version 3.1.0 or later.








The predictive and prognostic effects (hazard ratio [HR] and
95% confidence interval [CI]) of plasma protein and miRNA
levels were evaluated using a Cox proportional hazards model
using Efron and Breslow tie handling, respectively. The pre-
dictive effect was modeled as a protein–treatment interaction
effect and subjected to Akaike information criterion-based se-
lection to assess its association with OS and TTP. Models were
adjusted for age, sex, Eastern Cooperative Oncology Group
performance status, geographic region, a-fetoprotein (AFP)
level (<400 ng/mL vs 400 ng/mL), extrahepatic disease, and
macrovascular invasion. P values for HRs were corrected for
multiple testing using the Benjamini–Hochberg method.
Protein levels were measured as a continuous variable: HR
>1 indicates enhanced treatment benefit with regorafenib vs
placebo with decreased protein levels (or reduced benefit with
increased protein levels); HR <1 indicates enhanced treatment
benefit with increased protein levels. Subgroup analyses were
performed on proteins identified as predictive for OS and TTP
(adjusted P  .05): protein concentrations were dichotomized,
analyzed as quartile variables, and by subpopulation treatment
effect pattern plot analyses. A patient-wise protein composite
score was used to investigate whether groups of patient out-
liers, defined by exceptionally high or low protein levels
(ie, composite scores that were substantially high [>(quartile
3 þ 1.5*interquartile range)] or low [<(quartile 1 – 1.5*inter-
quartile range)]), have a predictive potential in HCC. The pro-
tein concentration composite score, and its interaction with
treatment, were used in clinical Cox models. Hierarchical
cluster analysis was carried out on proteins predictive for OS.
miRNA levels were measured as continuous or dichoto-
mized variables, with values dichotomized for miRNAs detected
in 50% of samples. An HR >1 indicates enhanced treatmentFigure 1. RESORCE patient
subgroups for biomarker
analyses.benefit with regorafenib vs placebo with increased miRNA
levels, whereas an HR <1 indicates an enhanced treatment
benefit with decreased miRNA levels. For dichotomized mi-
RNAs, HR relates to the presence vs absence of miRNA (ie, an
increase from no expression to detectable expression), with an
HR >1 indicating enhanced treatment benefit in the absence of
the miRNA. miRNAs identified as potentially predictive for OS
(with a Benjamini–Hochberg-adjusted P  .05) underwent a
quartile analysis. miRNA function was assessed by a correlation
analysis between miRNA and messenger RNA (mRNA)
expression data from The Cancer Genome Atlas and the sub-
sequent Gene Set Enrichment Analysis.10 The Spearman’s cor-
relation between the expression pattern of each potentially
predictive miRNA and all mRNAs was calculated based on The
Cancer Genome Atlas expression data from HCC tissue samples
(n ¼ 419). mRNAs were sorted by correlation, and the resulting
ranked gene lists underwent a Gene Set Enrichment Analysis11
based on curated gene sets from the Molecular Signatures
Database (C2 collection; Broad Institute, Inc., Cambridge,
MA).12Results
Patients
Between May 14, 2013, and December 31, 2015, 573
patients were enrolled and randomized (379 regorafenib,
194 placebo) in the RESORCE trial, of whom 567 initiated
treatment (374 regorafenib, 193 placebo).2 Samples for
biomarker analysis (archival tumor tissue and baseline
plasma samples) of appropriate quality were available for a
subset of enrolled patients (Figure 1).
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generally similar between the overall RESORCE patient
population and the protein and miRNA cohorts, except that
the miRNA cohort had a smaller proportion of Asian
patients than the overall cohort (Table 1). A number of
differences were observed between the overall RESORCE
cohort and the NGS and immune profiling cohorts due to the
small sample size in those cohorts.
Treatment outcomes (OS and TTP) in the protein and
miRNA cohorts were comparable to the overall RESORCE
cohort (Table 2). No statistical correlation with treatment
benefit was performed for the NGS and immune profiling
cohorts due to the small sample sizes.
Tumor NGS
In an effort to identify predictive genetic markers for
tumor growth inhibition in response to regorafenib, muta-
tion status in selected tumors from 12 regorafenib re-
sponders (1 complete response and 11 partial response)
was compared with 11 regorafenib progressors as assessed
by mRECIST. Of those, 17 had sufficient tumor content for
NGS analysis (7 partial responders and 10 progressors),
which revealed 49 somatic aberrations in 27 oncogenes and
tumor suppressor genes, the most frequent of which were
mutations in the promoter region of TERT (n ¼ 9, 53% [9 of
17]), followed by mutations in TP53 (n ¼ 7, 41% [7 of 17])
(Supplementary Figure 1). Although gene mutations in the
PI3K pathway (such as in PTEN, PIK3CA, or TSC1/2) were
equally distributed between responders and progressors,
mutations in CTNNB1 (encoding b-catenin in the Wnt
pathway) were found in 3 of 10 regorafenib progressors but
not in any regorafenib responders. One of the 7 responding
(and none of the progressors) patients had a VEGFA
amplification. The 5-gene signature identified by Nault
et al.9 was identified in only 5 of the 42 samples.
Immune Profiling
Due to the potential immunomodulatory role of regor-
afenib, we expanded the tissue-based analysis to investigate
the presence of immune gene expression signatures using a
cancer immune panel from which an immune cell score was
derived. Of 62 archival tumor samples, 46 passed quality
control (32 regorafenib, 14 placebo). Hierarchical clustering
of samples revealed 3 groups with low (21 of 46, 46%),
medium (17 of 46, 37%), and high (8 of 46, 17%) immune
cell scores (Figure 2A). In the regorafenib arm (n ¼ 32), low,
medium, and high immune cell scores were identified in 13
(41%), 13 (41%), and 6 (19%) patients, respectively
(Figure 2B). Kaplan–Meier analysis did not reveal a differ-
ence between low and medium/high immune cell groups for
median OS or median TTP; however, separation of the TTP
curves at a later time point may indicate a signal worth
investigating in future trials (Supplementary Figure 2). No
statistical testing was done due to the small sample size.
Protein Biomarkers
In the absence of identifiable predictive genetic bio-
markers, and due to the limited number of available tissuesamples, expression of 294 proteins was analyzed in
baseline plasma samples from 499 patients. The baseline
concentrations of 112 of 266 proteins valid for analysis
(28 proteins were consistently below the lower limit of
detection and therefore omitted) were identified as poten-
tially prognostic for OS (adjusted P  .05; Supplementary
Table 1) and 46 of 266 for TTP (adjusted P  .05;
Supplementary Table 2). The proteins prognostic for TTP
largely overlapped with those prognostic for OS (35 of 46).
Increased levels of both AFP (100% increase associated
with HR 1.09, 95% CI 1.07–1.12; P < .0001) and c-MET
(100% increase associated with HR 1.32, 95% CI 1.06–1.63;
adjusted P ¼ .025) were associated with a worse prognosis
for OS. Increased AFP levels were also associated with poor
prognosis for TTP (HR 1.05, 95% CI 1.02–1.07; P ¼ .001).
Five of 266 proteins were identified as predictive of
regorafenib treatment benefit for OS (angiopoietin 1 [ANG-
1], cystatin B, the latency-associated peptide of trans-
forming growth factor beta 1 [LAP TGF-b1], oxidized
low-density lipoprotein receptor 1 [LOX-1], C-C motif che-
mokine ligand 3 [MIP-1a]; adjusted P  .05; Table 3), with
decreased levels associated with enhanced treatment
benefit with regorafenib. This predictive effect was not
considered to be influenced by some of the key clinical
stratification and etiology variables (eg, hepatitis B and C,
Child–Pugh score, alcohol use, or pattern of progression).
None of the potentially predictive proteins were found to be
prognostic for OS. Baseline concentrations of 47 of 266
proteins were predictive for TTP (adjusted P  .05), with all
but 2 (calbindin and gelsolin) showing the same effect di-
rection as for OS (Supplementary Table 3). The proteins
predictive for TTP included the 5 proteins identified as
predictive for OS. Neither AFP or c-MET were identified as
predictive for OS or TTP treatment benefit. Regorafenib
treatment benefit for both OS and TTP was independent of
AFP and c-MET protein expression (Supplementary Table 4;
Supplementary Figure 3).
A subgroup analysis was performed on the 5 proteins
identified as predictive for regorafenib treatment benefit
for OS to further characterize the protein concentrations at
which the OS benefit may be reduced or improved. Protein
concentrations were dichotomized, analyzed as quartile
variables, and by subpopulation treatment effect pattern
plot analyses. Overall, the regorafenib treatment benefit
for OS was maintained using the different approaches,
with higher protein concentrations correlating with
reduced treatment benefit with regorafenib and vice versa
(Figure 3; Supplementary Figure 4; Supplementary
Figure 5).
Considering these results, we investigated whether there
was a group of patients who possibly did not benefit from
regorafenib treatment. Using a composite score approach
integrating expression levels across predictive proteins
(5 for OS; 47 for TTP), a small group of patients was iden-
tified (n ¼ 20 for OS; n ¼ 8 for TTP) with particularly high
protein expression levels for whom treatment benefit with
regorafenib was diminished compared with the rest of the
patient groups (OS: HR 1.21, 95% CI 1.13, 1.29; P < .0001;
TTP: HR 1.02; 95% CI 1.01–1.03; P < .0001). All patients
Table 1.Baseline Characteristics and Demographics for the Overall RESORCE Patient Population and Biomarker Cohorts



















Median age, yr (IQR) 64 (54–71) 62 (55–68) 68 (59–73) 69 (63–73) 64 (60–68) 64 (55–71) 62 (55–70) 64 (57–71) 64 (58–70)
Sex, n (%)
Male 333 (88) 171 (88) 14 (82) 23 (72) 13 (93) 289 (87) 148 (89) 208 (89) 95 (87)
Female 46 (12) 23 (12) 3 (18) 9 (28) 1 (7) 43 (13) 19 (11) 26 (11) 14 (13)
Race, n (%)
Asian 156 (41) 78 (40) 7 (41) 14 (44) 3 (21) 135 (41) 63 (38) 65 (28) 23 (21)
Black or African American 6 (2) 2 (1) 0 0 0 6 (2) 2 (1) 3 (1) 2 (2)
White 138 (36) 68 (35) 9 (53) 16 (50) 9 (64) 129 (39) 65 (39) 103 (44) 46 (42)
Other/not reported 79 (21) 46 (24) 1 (6) 2 (6) 2 (14) 62 (19) 37 (22) 63 (27) 38 (35)
Geographical region, ROW, n (%) 236 (62) 121 (62) 11 (65) 21 (66) 12 (86) 209 (63) 108 (65) 178 (76) 89 (82)
ECOG PS 1, n (%) 128 (34) 65 (34) 3 (18) 9 (28) 6 (43) 119 (36) 60 (36) 74 (32) 40 (37)
AFP 400 ng/mL, n (%) 167 (44) 89 (46) 3 (18) 8 (25) 4 (29) 145 (44) 73 (44) 99 (42) 47 (43)
Extrahepatic disease, n (%) 250 (66) 132 (68) 12 (71) 24 (75) 9 (64) 223 (67) 116 (69) 158 (68) 77 (71)
Macrovascular invasion, n (%) 117 (31) 59 (30) 5 (29) 8 (25) 3 (21) 108 (33) 48 (29) 81 (35) 33 (30)
Child–Pugh score,a n (%)
A5 244 (65) 118 (61) 15 (88) 23 (72) 8 (57) 210 (63) 97 (58) 146 (62) 67 (61)
A6 129 (34) 70 (36) 2 (12) 8 (25) 6 (43) 118 (36) 65 (39) 84 (36) 37 (34)
B7 5 (1) 5 (3) 0 1 (3) 0 3 (1) 5 (3) 3 (1) 5 (5)
B8 0 1 (1) 0 0 0 0 0 0 0
Hepatitis B, n (%) 143 (38) 73 (38) 6 (35) 8 (25) 2 (14) 120 (36) 58 (35) 67 (29) 30 (28)
Hepatitis C, n (%) 78 (21) 41 (21) 2 (12) 5 (16) 3 (21) 71 (21) 37 (22) 51 (22) 25 (23)
Alcohol use, n (%) 90 (24) 55 (28) 3 (18) 4 (13) 9 (64) 72 (22) 48 (29) 65 (28) 38 (35)
New intrahepatic lesions, n (%) 168 (44) 88 (45) 8 (47) 14 (44) 8 (57) 150 (45) 80 (48) 108 (46) 53 (49)
New extrahepatic lesions, n (%) 153 (40) 80 (41) 7 (41) 16 (50) 4 (29) 136 (41) 66 (40) 97 (41) 44 (40)
Progression (intra- and/or
extrahepatic), n (%)
307 (81) 156 (80) 14 (82) 27 (84) 11 (79) 267 (80) 133 (80) 192 (82) 93 (85)
Variables statistics were computed according to IVRS assignments. Percentages may not total to 100% due to rounding.
ECOG PS, Eastern Cooperative Oncology Group performance status; IQR, interquartile range; IVRS, Interactive Voice Response System; ROW, rest of the world (does not
include countries in Asia).











Table 2.Treatment Effect in the Overall RESORCE Patient Population vs Protein and miRNA Biomarker Cohorts
Population n Overall survival HR (95% CI) Time to progression HR (95% CI)
Overall population (stratified)a 573 0.62 (0.50–0.78) 0.44 (0.36–0.54)
Overall population (unstratified)a 573 0.67 (0.55–0.83) 0.43 (0.36–0.53)b
Protein biomarker cohort (unstratified)a 499 0.64 (0.51–0.80) 0.44 (0.35–0.54)
miRNA biomarker cohort (unstratified)c 343 0.63 (0.48–0.83) 0.49 (0.38–0.63)
aCox proportional hazards model using Efron tie handling.
bUsing Cox proportional hazards model with Breslow tie handling this value is 0.44 (0.36–0.54).
cCox proportional hazards model using Breslow tie handling.
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This composite score group of patients was not associated
with any particular patient demographic or disease char-
acteristic (data not shown). A cluster analysis performed on
the 5 predictive proteins showed variation in expression
levels across 3 distinct clusters (n ¼ 459, n ¼ 38, n ¼ 2),
which included the 20 patients with high protein expression
levels (Supplementary Figure 6).
miRNA
To gain further insights into gene expression and regu-
lation of oncogenic pathways in HCC, we evaluated the
possible regulatory role of miRNAs. Of 750 miRNAs
analyzed, 25 showed a multiplicity-adjusted (P  .05)
prognostic effect for OS (Supplementary Table 5). Nine
showed a multiplicity-adjusted predictive effect (P  .05)
for OS (Table 4): increased plasma levels of MIR30A,
MIR122, MIR125B, MIR200A, and MIR374B, decreased
levels of MIR15B, MIR107, and MIR320B, and absence of
MIR645 were all predictive of survival benefit with
regorafenib. MIR15B, MIR320B, and MIR200A were also
prognostic for OS (P  .05). Similar to the protein analysis,
this predictive effect was not considered to be influenced
by some of the key clinical stratification and etiology
variables. No miRNA was found to be predictive for TTP
(data not shown). Quartile analysis of miRNA concentra-
tions confirmed the direction of these findings (data not
shown).
A functional analysis of the predictive miRNAs identified
a list of 142 gene sets that showed concordance across at
least 6 of the 9 predictive miRNAs (false discovery rate of
0.01). Top gene sets showed consistent patterns related to
HCC subtypes and processes including liver cancer pro-
gression; metabolism of lipids, amino acids, bile acids, and
xenobiotics; glucuronidation; and doxorubicin resistance
(Supplementary Figure 7). The functional analysis of these
top gene sets revealed that improvement in response to
regorafenib could be observed in the G4/G5/G6 vs G1/G2/
G3 subtypes of the classification of Boyault et al,13 and in the
CTNNB1 and polysomy 7 subtypes of the classification of
Chiang et al.14 Both of these subtypes coincide with the S3
subtype of the Hoshida classification, which is characterized
in retrospective assessments by a hepatocyte-like pheno-
type, well-differentiated, and smaller tumors than other
subtypes (S1 or S2).15Discussion
In the absence of known biomarkers that predict clinical
benefit for systemic treatments in HCC for MKIs, we per-
formed a comprehensive assessment of unselected bio-
markers, including genetic mutations, immune gene
expression, circulating miRNA, and proteins in the phase 3
RESORCE trial of regorafenib in unresectable HCC. Our
results suggest that multiple proteins and miRNAs may be
predictive for OS in patients with HCC treated with regor-
afenib, and these results identify potential predictive bio-
markers for regorafenib in this setting for the first time.
Our analysis of the association between baseline plasma
levels of 266 proteins and responses to regorafenib treat-
ment identified 5 biomarkers (ANG-1, cystatin B, LAP TGF-
b1, LOX-1, MIP-1a) as possible predictors for OS, and 47
biomarkers, including the 5 predictive for OS, as possible
predictors for TTP. The treatment benefit with regorafenib
was maintained for the vast majority of patients in the
study, with only a small proportion of patients with
exceptionally high protein levels potentially deriving
reduced benefit. We were unable to link this outlier group to
particular patient characteristics. It is worth noting that the
predictive markers identified for OS and TTP did not include
well-known prognostic markers such as c-MET and AFP,16
both of which were confirmed as being prognostic for OS.
In fact, none of the 5 predictive markers for OS were iden-
tified as having prognostic relevance. Importantly, most of
the predictive candidates for OS and TTP are known to play
a role in inflammation and/or HCC pathogenesis, reflecting
the complex etiology of HCC: LAP TGF-b1 is a precursor to
TGF-b;17 MIP-1a induces immune cell infiltration promoting
liver fibrosis;18 LOX-1 plays a role in hypoxia-induced,
macrophage-derived foam cell formation and atheroscle-
rosis,19 which is interesting considering the immunomodu-
latory role of regorafenib;6 cystatin B has been reported to
be overexpressed in HCC;20 and ANG-1 plays a role in
angiogenesis and tumor progression.21 With the exception
of ANG-1, a ligand for the TIE2 receptor targeted by
regorafenib, the markers have not been identified as direct
regorafenib targets, although some may have an indirect
connection via its immunomodulatory function.5,6
We explored miRNAs in this cohort to gain insight into
the potential prognostic and predictive value of baseline
regulation of gene expression. miRNAs are small, noncoding
RNAs that regulate gene expression and are dysregulated in
Figure 2. Hierarchical clus-
tering of baseline gene
expression data for (A) all 46
samples (32 regorafenib, 14
placebo) and (B) 32 samples
from regorafenib-treated pa-
tients. DC, dendritic cell;
HBV, hepatitis B virus; HCV,
hepatitis C virus; N, no; NK,
natural killer; Th1, type 1 T
helper cell; Treg, regulatory T
cell; Y, yes.

















effect, HR (95% CI)a
Adjusted interaction
P value
ANG-1 1.12 (1.05–1.19) .019 1.10 (1.04–1.17) .017 1 ng/mL increase
Cystatin-B 1.46 (1.15–1.85) .040 1.42 (1.14–1.77) .018 2-fold increase
LAP TGF-b1 1.36 (1.12–1.65) .040 1.41 (1.18–1.68) .004 2-fold increase
LOX-1 1.35 (1.16–1.57) .009 1.78 (1.33–2.39) .003 1 ng/mL increase
MIP-1a 1.02 (1.01–1.04) .040 1.02 (1.00–1.03) .043 1 pg/mL increase
aAn HR >1 indicates enhanced treatment benefit with regorafenib vs placebo with decreased protein levels (or reduced
treatment benefit with increased protein levels).
bReference shows to what unit increase the HR is related to.
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identified as being prognostic for HCC and predictive for OS
in patients treated with regorafenib. Most of the miRNAs
have not been described previously in HCC pathogenesis,
with the exception of MIR122 and MIR200.22–25 For
example, MIR122 targets IGF1R, PDK4, LDHA, and
GALNT10, thereby regulating RAS/RAF/ERK signaling and
glycolysis, and has been reported to overcome resistance to
sorafenib.23 Interestingly, our functional analysis suggests
that response to regorafenib is associated with previously
described HCC molecular subtypes, with an improvement in
response to regorafenib in the Hoshida S3 subgroup.15
It is worth noting here the results from a previously
reported biomarker study derived from the STORM trial
that assessed the efficacy of sorafenib in an adjuvant setting
in patients with HCC following resection or ablation.26 In
this study, none of the tested biomarker candidates (pERK,
VEGA, pVEGFR2, reported signatures, mutations) predicted
a higher risk of recurrence or a benefit from sorafenib with
regard to prevention of HCC recurrence. Nevertheless, our
finding that the response to regorafenib is favorable in tu-
mors with properties that are consistent with the S3 sub-
type of the Hoshida classification is interesting and may
warrant further investigation.
Because HCC diagnosis algorithms do not require his-
topathologic confirmation of the disease, the optional
collection of archival tissue resulted in limited availability of
samples, precluding the identification of predictive effects
for OS and TTP because a much larger sample size would be
required. We therefore attempted to identify somatic aber-
rations associated with clinical response by mRECIST to
regorafenib by comparing the mutational profile of regor-
afenib responders and progressors. The results of
next-generation DNA sequencing were consistent with the
published mutational landscape of HCC.27,28 TERT and TP53
were the most frequently mutated genes, with additional
mutations identified in other genes that affect well-known
pathways involved in HCC pathogenesis, including PI3K
and Wnt signaling. Although 3 mutations in CTNNB1,
encoding b-catenin in the Wnt pathway, occurred only in
progressors, the small sample size precludes drawing any
meaningful conclusions from these results. Although only 1patient (a regorafenib responder as per mRECIST) had a
focal VEGFA amplification, this finding warrants further
investigation because it is the ligand for VEGFR, a target of
regorafenib, and has been reported to confer particular
sensitivity to sorafenib, although BIOSTORM was unable to
confirm these results.5,26,29
Although we were unable to identify genetic biomarkers
in archival tumor tissue, the immunomodulatory role of
regorafenib sparked interest in evaluating the role of
inflammation in HCC. Our results showed that the Pan-
Cancer Immune Profiling panel can be used to identify
tumors with medium/high scores for tumor-infiltrating
immune cells in almost 60% of samples. However, an as-
sociation between immune score and response to regor-
afenib was not assessed due to the small sample size. The
5-gene signature previously identified to be prognostic
for survival after liver resection in patients with HCC9
was identified in only 5 of the 42 samples, and therefore
its prognostic impact was not confirmed. No conclusive
results were obtained for the expression of c-MET.
The main limitation of this exploratory and retrospective
study is that it can only be considered to be hypothesis
generating for future trials in HCC. In addition, the small
number of archival tumor samples prevented us from car-
rying out correlative statistical analyses. For the protein and
miRNA analysis, continuous variables were used without
a concentration cutoff, which limits the possible clinical
interpretation of these findings; however, the improved
power of continuous variables over discrete variables to
detect a treatment effect was considered to be the best
approach for a comprehensive, hypothesis-generating study.
Thus far, rational biomarker selection has been unsuc-
cessful in identifying predictive markers for regorafenib in
colorectal cancer and gastrointestinal stromal tumors.3,4
The broader approach used in this study is not only bio-
logically warranted considering the heterogeneity of HCC
tumors,15,27 but is also needed due to the multiple targets
and pathways affected by MKIs such as regorafenib.7 Recent
protein expression analysis of regorafenib and sorafenib has
revealed a complex and distinct pattern of protein expres-
sion, which may provide some rationale as to why regor-
afenib is active in sorafenib-refractory patients. Disease
Figure 3. Protein dichoto-
mized subgroup analysis
for OS regorafenib treat-
ment benefit. Error bars
denote 95% CIs of the
treatment HR. Note, the
HR reference level line was























heterogeneity and multikinase inhibition also make it
perhaps unlikely that a single target will be identified that
can predict treatment benefit. Identifying a molecular
signature may be more successful and several HCC classi-
fication systems have been described, which until now have
not been linked to treatment or to prognosis.13–15
In conclusion, this hypothesis-generating study for bio-
markers predicting response to regorafenib treatment in
HCC has led to the identification of protein and miRNATable 4.Predictive miRNA Markers for OS and Their
Prognostic Effects
hsa-miRNA
miRNA predictive for OS
HR (95% CI)a Pb
MIR15B 0.37 (0.20–0.70) .002
MIR107 0.54 (0.37–0.81) .003
MIR320B 0.57 (0.41–0.81) .001
MIR122 1.35 (1.14–1.60) .0004
MIR374B 1.36 (1.11–1.65) .002
MIR200A 1.39 (1.15–1.68) .001
MIR30A 1.47 (1.14–1.88) .003
MIR125B 1.54 (1.19–1.99) .001
MIR645c 3.16 (1.52–6.55) .002
hsa, human (homo sapiens).
aFor all miRNAs except MIR645, an HR >1 indicates
enhanced treatment benefit with regorafenib vs placebo with
increased miRNA levels, whereas an HR <1 indicates an
enhanced treatment benefit with decreased miRNA levels.
bP values maintained significance following Benjamini–
Hochberg correction for multiple testing at an adjusted a 
0.05.
cFor MIR645, which was dichotomized by preprocessing, the
HR relates to the presence vs absence of the miRNA, with an
HR >1 indicating regorafenib treatment benefit in the
absence of miRNA.biomarker candidates and signatures that warrant further
validation in future studies. Although AFP and c-MET are
well-known prognostic markers for OS in HCC, with
elevated AFP recently described to be associated with
benefit to ramucirumab,30 we found no apparent association
between protein expression levels of AFP or c-MET and
regorafenib treatment benefit with respect to OS and TTP,
which rules them out as likely predictive biomarker
candidates.
Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2019.01.261.References
1. Llovet JM, Pena CE, Lathia CD, et al. Plasma biomarkers
as predictors of outcome in patients with advanced
hepatocellular carcinoma. Clin Cancer Res 2012;
18:2290–2300.
2. Bruix J, Qin S, Merle P, et al. Regorafenib for patients
with hepatocellular carcinoma who progressed on sor-
afenib treatment (RESORCE): a randomised, double-
blind, placebo-controlled, phase 3 trial. Lancet 2017;
389:56–66.
3. Tabernero J, Lenz HJ, Siena S, et al. Analysis of circu-
lating DNA and protein biomarkers to predict the clinical
activity of regorafenib and assess prognosis in patients
with metastatic colorectal cancer: a retrospective,
exploratory analysis of the CORRECT trial. Lancet Oncol
2015;16:937–948.
4. Demetri GD, Jeffers M, Reichardt P, et al. Mutational
analysis of plasma DNA from patients (pts) in the phase
III GRID study of regorafenib (REG) versus placebo (PL) in
tyrosine kinase inhibitor (TKI)-refractory GIST: correlating
1740 Teufel et al Gastroenterology Vol. 156, No. 6
CLINICAL
LIVERgenotype with clinical outcomes. J Clin Oncol 2013;31:
Abstr 10503.
5. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY
73–4506): a new oral multikinase inhibitor of angiogenic,
stromal and oncogenic receptor tyrosine kinases with
potent preclinical antitumor activity. Int J Cancer 2011;
129:245–255.
6. Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib in-
hibits growth, angiogenesis, and metastasis in a highly
aggressive, orthotopic colon cancer model. Mol Cancer
Ther 2013;12:1322–1331.
7. Kissel M, Berndt S, Fiebig L, et al. Antitumor effects of
regorafenib and sorafenib in preclinical models of
hepatocellular carcinoma. Oncotarget 2017;8:107096–
107108.
8. Frampton GM, Fichtenholtz A, Otto GA, et al. Develop-
ment and validation of a clinical cancer genomic profiling
test based on massively parallel DNA sequencing. Nat
Biotechnol 2013;31:1023–1031.
9. Nault JC, De Reynies A, Villanueva A, et al.
A hepatocellular carcinoma 5-gene score associated
with survival of patients after liver resection. Gastroen-
terology 2013;145:176–187.
10. Cancer Genome Atlas Research Network. Compre-
hensive and integrative genomic characterization of
hepatocellular carcinoma. Cell 2017;169:1327–1341.
e23.
11. Subramanian A, Tamayo P, Mootha VK, et al. Gene set
enrichment analysis: a knowledge-based approach for
interpreting genome-wide expression profiles. Proc Natl
Acad Sci U S A 2005;102:15545–15550.
12. Liberzon A, Subramanian A, Pinchback R, et al. Molec-
ular signatures database (MSigDB) 3.0. Bioinformatics
2011;27:1739–1740.
13. Boyault S, Rickman DS, de Reynies A, et al. Tran-
scriptome classification of HCC is related to gene alter-
ations and to new therapeutic targets. Hepatology 2007;
45:42–52.
14. Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of
VEGFA and molecular classification of hepatocellular
carcinoma. Cancer Res 2008;68:6779–6788.
15. Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative
transcriptome analysis reveals common molecular sub-
classes of human hepatocellular carcinoma. Cancer Res
2009;69:7385–7392.
16. Berretta M, Cavaliere C, Alessandrini L, et al. Serum and
tissue markers in hepatocellular carcinoma and chol-
angiocarcinoma: clinical and prognostic implications.
Oncotarget 2017;8:14192–14220.
17. Fabregat I, Moreno-Caceres J, Sanchez A, et al.
TGF-beta signalling and liver disease. FEBS J 2016;
283:2219–2232.
18. Czaja AJ. Review article: chemokines as orchestrators of
autoimmune hepatitis and potential therapeutic targets.
Aliment Pharmacol Ther 2014;40:261–279.
19. Crucet M, Wust SJ, Spielmann P, et al. Hypoxia en-
hances lipid uptake in macrophages: role of the scav-
enger receptors Lox1, SRA, and CD36. Atherosclerosis
2013;229:110–117.20. Lee MJ, Yu GR, Park SH, et al. Identification of cystatin B
as a potential serum marker in hepatocellular carcinoma.
Clin Cancer Res 2008;14:1080–1089.
21. Mitsuhashi N, Shimizu H, Ohtsuka M, et al. Angiopoietins
and Tie-2 expression in angiogenesis and proliferation of
human hepatocellular carcinoma. Hepatology 2003;
37:1105–1113.
22. Negrini M, Gramantieri L, Sabbioni S, et al. microRNA
involvement in hepatocellular carcinoma. Anticancer
Agents Med Chem 2011;11:500–521.
23. Xu Y, Huang J, Ma L, et al. MicroRNA-122 confers sor-
afenib resistance to hepatocellular carcinoma cells by
targeting IGF-1R to regulate RAS/RAF/ERK signaling
pathways. Cancer Lett 2016;371:171–181.
24. Boix L, Lopez-Oliva JM, Rhodes AC, et al. Restoring
miR122 in human stem-like hepatocarcinoma cells,
prompts tumor dormancy through Smad-independent
TGF-beta pathway. Oncotarget 2016;7:71309–71329.
25. Xue X, Zhang Y, Zhi Q, et al. MiR200-upregulated Vas-
ohibin 2 promotes the malignant transformation of tu-
mors by inducing epithelial-mesenchymal transition in
hepatocellular carcinoma. Cell Commun Signal 2014;
12:62.
26. Pinyol R, Montal R, Bassaganyas L, et al. Molecular
predictors of prevention of recurrence in HCC with sor-
afenib as adjuvant therapy and prognostic factors in the
phase 3 STORM trial [published online ahead of print
August 14, 2018]. Gut https://doi.org/10.1136/gutjnl-
2018–316408.
27. Guichard C, Amaddeo G, Imbeaud S, et al. Integrated
analysis of somatic mutations and focal copy-number
changes identifies key genes and pathways in hepato-
cellular carcinoma. Nat Genet 2012;44:694–698.
28. Kan Z, Zheng H, Liu X, et al. Whole-genome sequencing
identifies recurrent mutations in hepatocellular carci-
noma. Genome Res 2013;23:1422–1433.
29. Horwitz E, Stein I, Andreozzi M, et al. Human and mouse
VEGFA-amplified hepatocellular carcinomas are highly
sensitive to sorafenib treatment. Cancer Discov 2014;
4:730–743.
30. Zhu AX, Kang Y-K, Yen C-J, et al. REACH-2: A ran-
domized, double-blind, placebo-controlled phase 3
study of ramucirumab versus placebo as second-line
treatment in patients with advanced hepatocellular car-
cinoma (HCC) and elevated baseline alpha-fetoprotein
(AFP) following first-line sorafenib. J Clin Oncol 2018;
36:4003–4003.Received August 7, 2018. Accepted January 30, 2019.
Reprint requests
Address requests for reprints to: Michael Teufel, PhD, Bayer HealthCare
Pharmaceuticals, Building B200, 2B2208, Whippany, New Jersey 07981.
e-mail: michael.teufel@bayer.com.
Acknowledgments
The authors thank Georg Beckmann for his input into the study.
Editorial assistance in the preparation of this manuscript was provided by
Katrin Gudmundsdottir of OPEN Health Medical Communications (London,
UK), with financial support from Bayer.
Author contributions: Michael Teufel, Gerold Meinhardt, and Jordi Bruix
conceived and designed the study. All authors collected, assembled,








analyzed, and interpreted the data. All authors had access to the study data
and reviewed and approved the final manuscript. All authors agree to be
accountable for all aspects of the work, which includes ensuring that
questions related to the accuracy or integrity of any part of the work are
appropriately investigated and resolved.
The funder (Bayer) provided the study drug and worked with the principal
investigator (Jordi Bruix) and the study steering committee to design the
study. Data collection and interpretation, and preparation of this report, were
done by the investigators and the funder. Statistical analyses were
performed by the funder. All authors reviewed this report and approved the
submission for publication, had full access to the data, and vouch for the
completeness and accuracy of the data and adherence of the study to the
protocol.
Availability of the data underlying this publication will be determined
according to Bayer’s commitment to the EFPIA/PhRMA “Principles for
responsible clinical trial data sharing.” This pertains to scope, time point, and
process of data access. As such, Bayer commits to sharing upon request
from qualified scientific and medical researchers patient-level clinical trial
data, study-level clinical trial data, and protocols from clinical trials in
patients for medicines and indications approved in the United States and
European Union as necessary for conducting legitimate research. This
applies to data on new medicines and indications that have been approved
by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.clinicalstudydatarequest.com to request
access to anonymized patient-level data and supporting documents from
clinical studies to conduct further research that can help advance medical
science or improve patient care. Information on the Bayer criteria for listingstudies and other relevant information is provided in the “Study sponsors
section” of the portal. Data access will be granted to anonymized patient-
level data, protocols, and clinical study reports after approval by an
independent scientific review panel. Bayer is not involved in the decisions
made by the independent review panel. Bayer will take all necessary
measures to ensure that patient privacy is safeguarded.
Conflict of interest
Michael Teufel, Henrik Seidel, Karl Köchert, and Gerold Meinhardt are
employees of Bayer. Michael Teufel, Karl Köchert, and Gerold Meinhardt
own stock in Bayer. Richard S. Finn has received consultancy fees from
Astra Zeneca, Bayer, Bristol-Myers Squibb, Eisai, Merck, Pfizer, Roche,
Novartis, and Lilly. Josep M. Llovet reports receiving commercial research
grants from Bayer Healthcare Pharmaceuticals, Eisai, Bristol-Myers Squibb,
Ipsen, Blueprint, and Incyte and is a consultant/advisory board member for
Bayer Healthcare Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Eisai Inc.,
Celsion, Exelixis, Merck, Blueprint, Ipsen, Glycotest, Navigant, Leerink
Swann LLC., Midatech Ltd., Fortress Biotech Inc., Spring Bank
Pharmaceuticals, Nucleix, and Can-Fite Biopharma. Jordi Bruix has received
consultancy fees from Daiichi Sankyo, ArQule, Bayer, AbbVie, Bristol-Myers
Squibb, GlaxoSmithKline, Lilly, Kowa, Novartis, Roche, Onxeo, Terumo,
Sanofi Aventis, and Sirtex; advisory board fees from Bayer, AbbVie, Bristol-
Myers Squibb, Novartis, Roche, Onxeo, Terumo, Sirtex, MSD, and BTG; and
grants from Bayer.
Funding
The study was funded by Bayer. No grant number is applicable.
